Why Influencers Use the FDA to Bash Research Peptides

The FDA approves drugs. That much is true. What most people don't understand is who pays for that approval process, and once you understand that, the entire argument about "FDA approved" versus "not FDA approved" looks completely different.

Here is the basic structure of how drug approval gets funded. When a pharmaceutical company wants to bring a new drug to market, they submit an application to the FDA for review. That review costs money, meaning staff, time, infrastructure, and administrative overhead. And the way Congress decided to fund that review process is by charging the companies submitting the applications. This arrangement has a name: something called PDUFA, the Prescription Drug User Fee Act, which is the law that lets the FDA collect fees directly from the pharmaceutical companies it regulates. The fee for a single new drug application in 2024 is $4,198,000. And those fees don't cover a small slice of the budget. They cover approximately 65% of the entire human drug review budget at the FDA's drug centers.

The companies being regulated are paying for most of the cost of their own regulation.

That is not a conspiracy theory. That is the published federal budget. The question worth sitting with is what it means for how the system actually operates, because the answer to that question explains why peptides will never carry an FDA approval, and it has nothing to do with safety.

To understand the economics, you need to understand patents. When a pharmaceutical company develops a drug, they patent it, which gives them exclusive rights to manufacture and sell that compound for roughly 20 years. During that window, they are the only source. That exclusivity is what makes the math work, because bringing a single drug through the full approval process costs a median of $985 million in capitalized research and development costs according to a 2020 analysis published in JAMA Internal Medicine. You spend nearly a billion dollars, you patent the compound, and then you recoup that investment over 20 years of exclusive sales.

Peptides break this model completely.

Most research peptides are sequences of amino acids that occur naturally in the body or are close structural analogs to naturally occurring sequences, and naturally occurring sequences cannot be patented. There is nothing proprietary to protect. So the economic calculation a pharmaceutical company runs looks like this: spend close to a billion dollars on clinical trials and FDA approval, and then watch every competitor immediately manufacture the same peptide and undercut your price because you have no patent protection. No rational business makes that investment under those conditions, which means peptides do not go through formal approval, which means they exist outside the FDA's approved list, and which means people who want to use the FDA as a rhetorical weapon can point to that list and say "not approved, therefore unsafe."

The logic sounds clean until you understand why they aren't on the list.

Now there is a version of this criticism that does have real substance. Research chemicals sold without quality control, without proper synthesis verification, without third party purity testing, can absolutely be contaminated or misdosed, and that is a legitimate safety concern. The concern is real. But that concern is about sourcing and manufacturing standards, not about the underlying compound. Calling a peptide dangerous because it lacks FDA approval is like saying a knife is dangerous because it isn't sold at a licensed cutlery store. The licensing status of the seller tells you nothing about the sharpness of the blade.

What makes this worse is the revolving door between the FDA and the industry it regulates. A 2018 investigation published in Science found that 62% of FDA medical officers who left the agency between 2006 and 2019 went directly to work for pharmaceutical companies. Scott Gottlieb served as FDA Commissioner from 2017 to 2019 and joined Pfizer's board of directors the same year he left. The pharmaceutical industry spent $374 million on federal lobbying in 2023, the highest of any industry, with roughly three registered lobbyists for every single member of Congress. These aren't background details. This is the structure that determines which compounds get studied, which ones get approved, and which ones get left outside the system entirely.

So when someone uses "FDA approved" as a proxy for "safe" and "not FDA approved" as a proxy for "dangerous," they are either not understanding this system or they are using it deliberately. When that same person is selling peptides sourced from a compounding pharmacy, the argument gets cleaner. Compounding pharmacies operate under a different regulatory framework that allows them to sell compounds that wouldn't otherwise be approved, which means the seller gets to criticize research peptides for lacking FDA approval while their own product also technically lacks FDA approval in the standard sense. The distinction they're drawing is between regulatory categories, not between safety profiles, and most of their audience doesn't know enough about those categories to catch it.

The practical implication for anyone trying to navigate this: the question to ask about any peptide or compound is not whether the FDA has approved it. The question is whether there is third party certificate of analysis testing confirming purity and identity, whether the source has a verifiable track record of quality control, and whether there is research supporting the mechanism you care about. Those are the questions that actually predict whether a compound will do what it's supposed to do without causing harm. "FDA approved" answers none of them.

The FDA approval process was built for patentable pharmaceuticals. Compounds that fall outside that economic model will never have a path through it, not because they are dangerous, but because no one with the resources to fund approval has a financial reason to do so. That's the whole system. Once you see it, "FDA approved" stops being a safety standard and starts being a market entry signal for something a pharmaceutical company thought was worth a billion dollars to protect.

---

References

1. FDA PDUFA Fee Schedule — Federal Register (published annually). FY 2024 application fee: $4,198,000.
2. FDA Budget Justification to Congress — PDUFA user fees fund approximately 65% of CDER/CBER human drug review budget.
3. Piller, C. (2018). "Is FDA's revolving door open too wide?" Science. Found 62% of FDA medical officers who left between 2006-2019 went to work for pharmaceutical industry.
4. OpenSecrets.org — Center for Responsive Politics. Pharmaceutical/health products industry spent $374 million on federal lobbying in 2023, #1 ranked industry. Approximately 1,500-1,800 registered lobbyists (roughly 3:1 ratio to members of Congress).
5. Scott Gottlieb served as FDA Commissioner 2017-2019, joined Pfizer board of directors in 2019.
6. Wouters, O.J., McKee, M., Luyten, J. (2020). "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." JAMA Internal Medicine. Median capitalized cost: $985 million per drug.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness